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Background: Understanding the pathogenic mechanism of pancreatic cancer associated diabetes (PCDM) might
help yield biomarkers for the early diagnosis of pancreatic cancer (PC) from population with new-onset diabetes.
In the current study, we sought to determine the role of macrophage migration inhibitory factor (MIF) in PCDM
pathogenesis.
Methods: The protein and mRNA levels of MIF in paraffin-embedded human PC samples, chronic pancreatitis
specimens, and normal pancreas were measured by immunohistochemistry and quantitative reverse-transcriptase
polymerase chain reaction. We measured serum levels of MIF in PC patients and controls. The biologic impacts of
MIF overexpression on insulin secretion function of mice islets and β cells (HIT-T15) were investigated in vitro.
Results: MIF expression was significantly increased in pancreatic cancer tissues compared with chronic pancreatitis
or normal pancreas specimens. The insulin secretion function of both islets and HIT-T15 cells was impaired by
indirect co-cultured with PC cells or treated with conditioned media from them. Stable MIF knock-down significantly
decreased the diabetogenic effect of PC cells, while MIF knock-in HPDE6 cells demonstrated a strong inhibitory effect
on insulin secretion function of islets and HIT-T15 cells. MIF impaired βcell function by depressing the Ca2+ currents,
decreasing L-type Ca2+ channel α1 subunit protein expression level, and enhancing p-Src activity. Mean serum level of
MIF was significant higher in new-onset diabetes associated PC patients in comparison with other groups.
Conclusions: MIF is up-regulated in patients with pancreatic cancer and causes dysfunction of insulin secretion in
β-cells.
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Pancreatic cancer (PC) is a highly malignant neoplasm
and the forth-leading cause of cancer death. The 5-year
survival of PDAC is only about 5%, and this figure has
remained nearly unchanged over the past two decades
[1,2]. Highlighting its dismal prognosis, principally because
the cancer-specific symptoms occur late, and a screening
strategy for asymptomatic patients of sporadic pancreatic
cancer has not been established [3,4]. Thus, the discovery* Correspondence: zqb_sysu@126.com; chenrf_sysu@163.com
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great significance.
The relationship between diabetes mellitus (DM) and
PC has long been studied for decades, but it became
more interesting since the existence of a bidirectional
association between the two entities was discovered: the
risk of pancreatic cancer is high with new-onset diabetes
(5–8-fold) whereas the risk levels out at about 1.5-fold
in long-standing diabetes patients [5-7]. Recently, com-
pelling studies suggests that while long-standing diabetes
is an etiologic factor for pancreatic cancer, new-onset
diabetes is caused by the cancer [5,8]. Importantly,
new-onset diabetes is present in nearly half of all
pancreatic cancer, and these patients display diabetes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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radiologically detectable [8]. These recent finding
indicated a potential screening strategy for PC using
manifestation of new-onset diabetes as an indicator of
underlying pancreatic cancer. However, given that the
primary type 2 diabetes and PC associated new-onset
diabetes are still clinically indistinguishable, a reliable
biomarker for PC associated new-onset diabetes remains
to be identified before this screening strategy becomes
cost-effective [8,9].
Understanding the mechanism of PC associated
new-onset diabetes has broader implications for early
diagnosis of pancreatic cancer, but the pathogenesis
of PC-associated diabetes is still unknown. Current
epidemiologic, clinical, and in vitro studies suggest
that tumor-secreted products is more likely related
toβ-cell dysfunction in PC associated diabetes rather a
local tumor effect such as infiltration or obstruction
[9,10]. Inflammation has been proposed to contribute
to β -cell dysfunction in both type 1 diabetes (T1DM)
and type 2 diabetes (T2DM) [11,12]. Indeed, islets
from diabetes patients show immune cell infiltration
and increased cytokine and chemokine expression
[13]. Macrophage migration inhibitory factor (MIF) is
a pro-inflammatory cytokine and an important regula-
tor of innate immunity [14]. Although first described
as an immune cell product, a much higher MIF level
was found in kinds of human cancer and cancer-prone
inflammatory diseases, including chronic pancreatitis and
pancreatic cancer [14,15]. In addition, many functions of
MIF support its potential involvement in diabetes, such as
MIF inhibits INS-1 cell proliferation, MIF deficiency in
atherosclerosis-prone mice impairs the development of
insulin resistance, and MIF contributes to beta cell death
during exposure to toxic nutrients, palmitic acid, or
glucose [16,17]. Despite the compelling evidence suggesting
MIF play role in cancer and diabetes, there is no data
whether MIF could promote PC associated diabetes
(PCDM) and distinguish it from T2DM.
In this study, we aimed to demonstrate the biological
relevance of MIF in pancreatic cancer induced β-cell
dysfunction, and to identify whether it could serve as a
potential biomarker of PC associated diabetes that can
distinguish it from type 2 diabetes.
Materials and methods
Cell culture
HIT-T15 pancreatic β-cells were kindly provided by
the Endocrine laboratory of Sun Yat-sen memorial
hospital, and were maintained in the RPMI 1640
(Gibco, Grand Island, NY) with 10% fetal bovine
serum (FBS), 2 mmol/L glutamine, 100 IU/ml Penicillin
and 100 mg/ml streptomycin. Human primary pancreatic
cell lines were purchased from the American Type CultureCollection and grown in RPMI 1640 (Gibco, Grand Island,
NY) and DMEM (Gibco, Grand Island, NY) with 10%
FBS, 1% penicillin/streptomycin. HPDE6 (immortalized
human pancreatic ductal epithelial cells) was obtained
form Dr. Zhang SN (Sun Yat-Sen University, Guangdong,
China).
Islet isolation
For isolation of pancreatic islets, normal adult male
inbred C57BL/6 mice were used, and 12-weeks old ones
were sacrificed by cervical dislocation and their pancreas
were removed. Islet cells were isolated from perfusion
of the pancreas and digested using by collagenase V
(Sigma-Aldrich, St Louis, MO) in Hank’s balanced salt
solution followed by handpicking and placed in a 96-well
plate (10 islet per well), grown overnight in RPMI 1640
(Gibco, Grand Island, NY) containing 10% FBS, 10 mmol/L
HEPES, 5 μl/Lβ-mercaptoethanol, 2 mmol/L glutamine,
1 mmol/L Sodium Pyruvate, 100 IU/ml penicillin, and
100 m g/ml streptomycin in a humidified (5% CO2, 95%
air) atmosphere at 37°C.
RNA isolation and quantitative real-time PCR
Quantitative real time PCR (qPCR) was performed for MIF
mRNA with GAPDH as an internal control. RNA was
isolated from frozen pancreatic cancer tissues, chronic
pancreatitis tissues, and pancreatic cell lines using the
RNA easy spin mini-column kit (Qiagen Sciences,
Valencia, CA) according to the manufacturer’s instructions,
and total RNA was extracted. Total RNA was converted to
cDNA by reverse-transcription using oligodT primers and
SuperScript II reverse transcriptase (Invitrogen). For real-
time quantitative PCR, three replicates of each sample were
amplified and analyzed with a Roche Light-Cycler (Roche,
Basel, Switzerland). Reactions were in a 20 μl volume by
using SYBR Green reaction mix (Qiagen Sciences) with
0.5 mM of primer. Relative gene expression levels were
determined using the ΔCt-method.
MIF knock-in and knock-down
Lentiviral vectors were used to generating the stable
MIF-over expressing and shRNA MIF-knockdown cells
as described by Funamizu et al. Briefly, Lentiviral MIF
knock-in constructs (pLOC-MIF), and lentiviral MIF
knock-down constructs (pGIPZ-shRNA 1 and shRNA2)
were obtained from Open Biosystems (Rockford, IL).
Lentiviral particles were produced by transfecting 239 T cells
according to the manufacturer’s protocol. Viral supernatants
was collected after 72 hours following transfection, and the
particles were concentrated by using LentiXTM Concentrator
over night at 4°C (Clontech, Mountain View, USA), the
aliquots were stored at −80°C. The titers of the concentrated
particles were measured before using. The PANC-1 and
CAPAN-2 cells were (5× 105cells/well)were seeded in 6-well
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10% FBS for 24 hours before infection. For screening,
blasticid in (10 μg/mL) for MIF Knock-in cells and
puromycine (10 μg/mL) for MIF knock-down cells
were added to the medium 72 hours after infection.
The medium was replaced every 2 days for 2–3 weeks.
Western blotting
Cells were washed in PBS and lysed with RIPA buffer
(Invitrogen, Carlsbad, CA). For equal protein loading, a
Bicinchoninic acid protein assay kit (Pierce) was used to
calculate protein concentration in each sample. Equivalent
amounts of proteins were separated by SDS-PAGE and
transferred to polyvinylidene fluoride (PVDF) membranes
for immunoblotting. The membranes were blocked in 5%
fat-free milk for 2 hours at room temperature, washed 3
times, and then the membranes were incubated with the
following primary antibodies: rabit anti-human MIF
polyclonal antibody (1:1000, Abcam, Cambridge, MA),
rabit anti-human β-actin antibody (1:1000, Abcam,
Cambridge, MA), rabit anti-human GAPDH antibody
(1:1000, Abcam, Cambridge, MA), anti-Src and anti-p-Src
Tyr418 (1:500, Cell Signaling Technology, USA), and rabbit
polyclonal to LCC α 1C (1:200; Alomone, Israel). β- actin
or GAPDH was used for loading controls. Horseradish
peroxidase-conjugated secondary antibodies (Cell signaling
technology) and an ECL chemiluminescence kit (Pierce)
were used to detect bound antibody.
Immunohistochemistry
Paraffin-embedded samples of the primary carcinomas
were stained for RASSF6. The pathological sections were
deparaffinized in xylene and rehydrated in grade series
of ethanols followed by heat-induced epitope retrieval in
citrate buffer (PH = 6.0). Antigen retrieval was carried out
in 10 mmol/l citrate buffer (pH = 6.0) in a microwave oven
for 15 min. The activity of endogenous peroxidase was
exhausted with 3% hydrogen peroxide for 10 min at room
temperature. Rabbit MIF polyclonal antibody (Abcam,
Cambridge, MA) were applied over night at 4°C at optimal
working concentration of 1:300. After sufficient phosphate
buffered saline rinses, sections were stained with goat
anti-rabbit polymers.
Voltage-dependent Ca2+ channel current recording
VDCC Ca2+ currents of HIT cell were monitored in a
voltage-clamped HIT-T15 cell using the whole cell
patch-clamp technique as previously described [18]. The
extracellular recording solutions contained 140 mmol/L
tetraethylammonium chloride, 5 mmol/L 4-aminopyridine,
5.4 mmol/L KCI, 1 mmol/L MgCI2, 2 mmol/LBaCI2,
2 mmol/L glucose, an d 10 mmol/L HEPES, and the pH
was adjusted t o 7.3 with KOH. The pipette (intracellular
solution) contained 105 mmol/L N-methylglucamine,15 mmol/L 1,2-bis-aminophenoxyethane-N,N,N',N"tetra-
acetic acid, 10 mmol/L HEPES, 2.5 mmol/L MgCI2, and
110 mmol/L L-aspartic acid, and the pH was adjusted to
7.2 with N-methylglucamine. MIF was also diluted to the
appropriate concentration (0 mmol/L, 20 mmol/L, and
40 mmol/L) in the bath solution. The VDCC currents
were recorded by a 300 ms step pulse ranging from −80
to +60 mV, the holding potentials were selected at −40 mV
which represents mostly the activity of L-type VDCCs,
and the out ward voltage-dependent K + currents or
inward T-type VDCC currents were largely inactivated,
respectively.
Indirect co-culture of pancreatic cancer cells and β-cells
or islets
HIT-T15 pancreatic β-cells (2 × 105cells/well) were seeded
in 12-well culture plates (Corning®) in modified PRIM
1640 medium supplemented with 10% FBS, 2 mmol/L
glutamine, 100 IU/ml penicillin, 0.1 mg/ml streptomycin,
and 5.5 mmol/L glucose. Isolated islets were dispersed
into single cells by trypsin enzymatic digestion and
gentle pipetting every 60s for 5 minutes, seeded in
12-well culture plates (cells of 20 islets per well), and
then maintained in modified PRIM 1640 (Gibco, Grand
Island, NY) supplemented with 10% FBS, 100 IU/ml
penicillin, 0.1 mg/ml streptomycin, and 11 mmol/L
glucose. Pancreatic cancer cells (2 × 105cells/culture
insert) were seeded into the transwell culture inserts
of 1.0 μm pore size (Corning® BioCoat™) in PRIM
medium supplemented with 10% FBS, penicillin, and
streptomycin. After 24 hours, the culture insets were
placed into the 12-well plates containing HIT-T15 cells,
and incubation was continued up to 1 day in modified
RPMI1640 medium supplemented with 1% FBS, glutamine,
5.6 mmol/L glucose, penicillin, and streptomycin.
Insulin secretion assay
The effect of MIF on insulin secretion function was evalu-
ated through two models: the indirect co-culture method,
and the adding supernatants method. In the indirect
co-culture method, both the HIT-T15 cells and the islets
cells were co-cultured with PANC-1, Capan-2, or HPDE6
cells respectively in the 12-well transwell plates as
mentioned above. 24 hours after co-culture, the medium
was replaced with fresh modified KRB buffer (136 nM Na,
4.8 nM KCl, 2.5 nM CaCl2, 1.2 nM KH2PO4, 1.2 nM
MgSO4, 5 nM NaHCO3, 10 nM HEPES, and 0.1% BSA,
pH 7.3) containing 2.5 mmol/L glucose for 30 min at 37°C
(basal secretion). And then, the KRB was removed from
each well (collected for insulin assay, stored at −80°C) and
replaced by the same modified KBR buffer containing
16.7 mmol/L glucose for 30 min (stimulatory secretion).
At the end, this KBR was also collected and stored at −80°C.
In the other method, the supernatants of PANC-1, Capan-2,
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(the same modified PRIM1640 medium used in the
co-cultured method) of HIT-T15 cells and islet cells,
respectively. After 24 hours, the medium was replaced
with fresh modified KRB buffer (136 nM Na, 4.8 nM
KCl, 2.5 nM CaCl2, 1.2 nM KH2PO4, 1.2 nM MgSO4,
5 nM NaHCO3, 10 nM HEPES, and 0.1% BSA,
pH 7.3) containing 2.5 mmol/L glucose and supple-
mented with or without the supernatants for 30 min at
37°C (basal secretion). And then, the KRB was also re-
moved, collected, and replaced by the same modified KBR
buffer containing 16.7 mmol/L glucose, supplemented with
or without the supernatants, for 30 min at 37°C (stimulatory
secretion). This KBR was also collected and stored at −80°C.
At last, Insulin level was measured. HIT Cells and islets cells
were lysed in RIPA buffer and total protein determined by
BCA Protein Assay Kit (Pierce, USA). The insulin dose was
normalized to cellular protein.
Evaluation of serum MIF levels
The serum MIF levels were measured in 70 patients
without PC and other malignant disease or immune
disease, and in 105 patients diagnosed with pancreatic
cancer. Informed consent was taken from all subjects.
The Human Research Ethics Committee of Sun Yat-sen
Memorial Hospital approved all aspects of this study.
Blood samples were collected immediately after the
patients was admitted to the hospital under fasting stateFigure 1 MIF is overexpressed in human pancreatic cancer tissues, espe
history or chronic pancreatitis patients. Immunohistochemical analysis of M
sporadic cytoplasmic staining in gland, and weak to moderate, diffused cytopla
weak to moderate MIF staining, but MIF expression in adjacent glands was mu
increased, diffused cytoplasmic MIF expression in both tumor cells and adjacen
tissues form patients with different DM history and chronic pancreatitis tissues.
in new-onset DM PC tissues was observed.at about 8 AM in a 5 ml dying vacuum tube, and then
the serums were separated and collected after blood
clotting, stored in liquid nitrogen. The levels of serum
MIF were quantified using commercial ELISA kits
according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA).
Results
MIF expression is associated with diabetes history in
resected pancreatic cancer tissues
A total of 84 pancreatic cancer patients were included
in the immunohistochemistry and qRT-PCR analysis
(Additional file 1: Table S1 and Additional file 1: Table S2).
On immunohistochemistry, in the normal pancreata
(Figure 1A), the islets were moderate stained for MIF,
while glands and ducts stained weakly. Chronic pancrea-
titis tissues showed a stronger MIF staining than normal
pancreata both in islets, glands and ducts (Figure 1B). In
comparison, pancreatic cancer specimens showed a strong
positive MIF staining (Figure 1C); MIF expression was
found not only in cancer cells but also neighboring ducts,
acini, and islets. The islets adjacent to the cancer also
showed a diffused over-expression pattern.
MIF gene expression analysis was performed in resected
samples using qRT-PCR (Figure 1D). Quantitative RT-PCR
on RNA isolated from human pancreatic cancer tissues
showed higher MIF expression in patients with new-onset
DM compared with patients with long-term DM or thosecially in those with diabetes, compared with PC patients without DM
IF in paraffin. sections shows: (A) Chronic pancreatitis showing weak,
smic staining in islets (red arrow). (B) Normal pancreas, islets also showed
ch weaker and frequently lost. (C1&C2) In pancreatic cancer tissues, an
t islets (red arrow). (D) Real-time quantitative PCR on pancreatic cancer
Compared with the other groups, an significant increased MIF mRNA level
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between the group of chronic pancreatitis and non-DM
pancreatic cancer.
MIF overexpression impairs insulin secretion
Because MIF was overexpressed in pancreatic cancer
cells, we used MIF shRNA to knock down MIF in
PANC-1 and Capan-2 cells. Vice versa, a MIF overex-
pressing immortalized human pancreatic ductal epithelial
cell line was generated. The MIF expression was analyzed
by western blot and real-time PCR, results showed
that stable MIF-over expressing immortalized human
pancreatic ductal epithelial cells (HPDE6) and shRNA
MIF-knockdown pancreatic cancer cells (PANC-1 and
Capan-2) were generated (Figure 2A).
The diabetogenic effect of MIF on glucose-stimulated
insulin secretion from HIT cells and isolated mouse
islets was studied first through adding rMIF into the
medium directly. As shown in Figure 2B, we observed
a dose–response relationship between MIF concentration
and the inhibiting effect on insulin secretion. When islets
cells (Figure 2B1) or HIT cells (Figure 2B2) were stimulated
with 16.7 mmol/L glucose following exposure to MIF at
concentrations of 40 nmol/L, insulin secretion was reduced
to 52% and 46.7%, respectively (P <0.01, n = 6).
After indirectly co-cultured with PANC-1 or Capan-2
cells, or treated with PANC-1/Capan-2 supernatants
(volume of original medium of insulin secreting cells:
volume of supernatants is about 1:1), both islet cells
and HIT cells showed impaired glucose-stimulated
(16.7 mmol/L) insulin secretion function, and shRNA-
mediated knockdown of MIF ameliorated the inhibitory
effect of PANC-1 and Capan-2 cells on insulin secretion
capacity. The immortalized epithelial cell line HPDE6 had
little impact on insulin secretion, while MIF-transgene
expressing HPDE6 cells or its supernatants showed a
strong inhibitory effect on insulin secretion (Figure 2C
and Figure 2D).
rMIF stimulation depresses HIT cell VDCC Ca2 + currents
Cultured HIT cells were pretreated with 20, 40 or
60 nmol/L rMIF for 24 h, and whole-cell evoked Ca2+
currents (L-type Ca 2+ currents, ICa,L) were recorded,
and the current densities were calculated (n = 6). As
shown in Figure 3A and 3B, on treatment with 20, 40, or
60 nmol/L rMIF, the ICa,L of HIT-T15 cell were depressed,
and the peak current density of ICa,L was reduced, with
reductions of 16%, 52% and 57%, respectively. The peak
inward current densities fell from −31.6 ± 3.9 pA/pF in
controls (n = 6) to −26.6 ± 3.3 pA/pF (20 nM, P < 0.05),
to −15.1 ± 4.0 pA/pF (40 nM, P < 0.01), to −13.2 ± 4.1
pA/pF (60 nM, P < 0.01).
In order to evaluate the recovery from inactivation,
currents were elicited by the double-pulse protocol withan interval separating two pulses increased from 0 to
200 ms. The time constants (τ) of ICa,L recovery from
inactivation in the HP (Holding potential) of −40 mV
were 96.2 ± 7.9 ms, in the controls (n = 3), significantly
less than 136.7 ± 9.7 ms (n = 3), and 165.36 ± 12.9 ms
(n = 3) in the presence of 20 nmol/L or 60 nmol/L
rMIF, respectively. In addition, the I/Imax values in
the rMIF-treated groups were significantly decreased
in comparison with those of the control group (n = 3,
P < 0.01) (Figure 3C). These results suggest that rMIF
also impairs L-type Ca2+ channel (LCC) function through
inhibiting the recovery speed of ICa,L from inactivation.rMIF down-regulates the expression of channel protein
The LCC density was also associated with insulin secretion
function. Therefore, to evaluate if MIF can affect channel
expression level, we evaluated the expression of LCC α1
subunit before and after rMIF treatment. A dose-effect
relationship was observed (Figure 4A), data revealed that
the LCC α1 protein level gradually reduced with the
increase of rMIF concentration. Meanwhile, cells pretreated
with 20 and 40 nmol/L rMIF showed a more obvious
extent of reduction in LCC α1 expression level compared
with those treated with 60, 80 and 100 nmol/L rMIF, which
was in consistent with the findings in the insulin secretion
experiment. Quantification of western blot results revealed
that α1C subunit protein level of HIT cells dropped
22% (P < 0.05) and 42% (P < 0.01) after treatment
with 20 and 40 nmol/L rMIF, respectively. There was
no statically difference in α1Csubunit protein level
between cells receiving 60, 80, and 100 nmol/L rMIF
pretreatment, and cells receiving 100 nmol/L rMIF
pretreatment showed a slightly decreased viability
(data not shown). Which indicate that 40-60 nmol/L rMIF
might cause maxium efficiency on regulating α1C subunit
protein level. The α1C subunit mRNA levels were also
decreased after rMIF treatment (Figure 4A). Also, 20 and
40 nmol/L rMIF treatment showed more efficient impact
on down-regulating α1C subunit mRNA (felled 30%
and 39%, respectively), and concentrations higher than
40 nmol/L showed no further effect on regulating
α1C mRNA.rMIF-induced β cell dysfunction is partially mediated by
regulating Src family tyrosine kinase acitvity
Because it has been reported that the Src exert a tonic
inhibitory role on Ca2+ dependent insulin secretion,
the next series of experiments was performed to
determine whether the effect of MIF on insulin secretion
and Ca2+ channel protein expression were through
regulating the Src activity. We found that 40 nmol/L rMIF
treatment markly increased the level of p-Src (p < 0.01,
n = 3), and both 15 μM PP1 and 2 μM AZD0530
Figure 2 (See legend on next page.)
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Figure 2 MIF inhibits glucose-stimulated insulin secretion and contributes to the insulin inhibitory effect of PC cells. (A) Stable shRNA
MIF-knockdown (sh-Capan-2, sh-PANC-1) cells and MIF-over expressing cells (MIF-HPDE6) were generated by using lentiviral vectors. Vector
controls showed no regulatory effect on MIF expression. (B1&B2) Degree of inhibitory effect on insulin releasing improved with the increasing
concentration of MIF from 0 to 100 nmol/L both in PANC-1 (B1) and Capan-2 (B2) cell lines. A most significant drop of insulin secretion level was
observed following exposure to MIF at concentrations of 40 nmol/L, reduced to 52% in islets and 46.7% in HIT-T15 cells, respectively, 0 nmol/L
rMIF act as control groups. (P <0.01, n = 6). (C1&C2) MIF mediated the inhibitory effect of PC cells on insulin secretion capacity. C1: after indirectly
co-cultured with PANC-1 or Capan-2 cells, islet cells showed impaired glucose-stimulated insulin secretion function, shRNA-lentivirus mediated
MIF inhibition ameliorated the insulin secretion capacity; the immortalized epithelial cell line HPDE6 decreased insulin secretion a little, while
MIF-transgene expressing HPDE6 cells showed a strong inhibitory effect on insulin secretion. C2: after adding supernatants into the culture
medium of islet cells, a same effect of MIF was observed. (D1&D2) The same role of MIF was observed in HIT-T15 cells just as it shown in the
islet cells. Glc: glucose; *:p<0.01, Student’s t-test. Sh-PANC-1: shRNA MIF-knockdown PANC-1 cell line; Sh-Capan-2: shRNA MIF-knockdown Capan-2
cell line; MIF-HPDE6: MIF-transgene overexpression HPDE6 cell line; pGIZ-PANC-1, pGIZ-Capan-2, and pLOC-HPDE6 are null vector transfected cell
lines as controls to exclude the effect of vector on expression of potential genes coding proteins which might regulate insulin releasing.
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ylation as expected (p < 0.01, n = 3) (Figure 4B).
Next, the effect of PP1 and AZD0530 on α1C subunit
level was tested (Figure 4C). We found there was no
significant change in α1C protein and mRNA levels
when HIT-T15 cells were incubated with 15 μM PP1 or
2 μM AZD0530 for 24 h (GAPDH was internal control
for western blot, β-actin was internal control for
qRT-PCR, 0.93 ± 0.06 and 0.91 ± 0.05, respectively),
but levels of α1C subunit protein were significantly
higher in HIT-T15 cells treated with rMIF plus PP1
or AZD0530 in comparison with cells treated with rMIF
along (p < 0.01, n = 3, both). This finding reflect that Src
family kinase is likely to be involved in the rMIF-induced
α1C down regulation. In addition, the diabetogenic
effect of 40 nmol/L rMIF treatment on glucose-
stimulated (16.7 mmol/L) insulin secretion function of
both HIT-T15 cells and islet cells was also reversed
through co-treatment with 15 nM PP1 or 2 nM AZD0530
(p<0.01, n = 6, both) (Figure 4D).
Since the HIT-T15 cell is a rat-derived insulin-
secreting cell line, and some aspects of protein expres-
sion and exocytotic characteristics differ between this
cell line and islets, we further confirmed the findings
in pancreatic cancer cell line and isolated islet cells.
As shown in Figure 4E, the α1C protein was down-
regulated and the p-Src was up-regulated through
co-cultured with PANC-1 and Capan-2 cells. Following
shRNA-mediated knockdown of MIF, the regulatory effect
of PANC1 and Capan-2 cells on α1C protein expression
and Src activity was abolished. Vice versa, MIF-transgene
expressing enabled HPDE6 cells to reduce α1C protein
expression and to increase p-Src level. On the aspect
of insulin secretion, the regulatory effect of PANC1,
Capan-2, and MIF-expressing HPED6 cells on insulin
secretion from islet cells was also significantly ameliorated
by using PP1 or AZD0530 (131% vs. 59%, P<0.01, n = 6;
127% vs. 53%, P<0.01, n = 6; 133% vs. 60%, P<0.01, n = 6;
respectively) (Figure 4E).MIF is a candidate serum biomarker of new-onset
diabetes associated pancreatic cancer
As shown in Figure 5, the serum levels of MIF in the
following five group patients were examined: pancreatic
cancer patients without diabetes, pancreatic patients
with more than two years history of diabetes, pancreatic
patients with less than two years history of diabetes
(new-onset diabetes), healthy subjects with normal
fasting glucose, and T2DM patients (without any other
immune diseases or tumor) diagnosed within in two years.
The five groups were age (±3 years) and sex-matched, and
the TNM stage of three pancreatic cancer groups are not
significant different (Additional file 1: Table S3 and
Additional file 1: Table S4). A scatterplot of MIF
levels in the 5 groups is shown in Figure 5A. Mean
plasma levels (ng/ml) were significant higher in 35
new-onset DM PC patients (32.1 ± 9.6) compared with
35 non-DM PC patients (17.3 ± 6.4, P <0.001), 35
long-term DM PC patients (20.4 ± 6.6, P <0.001), 35 nor-
mal fasting glucose healthy people (14.3 ± 5.8, P < 0.001),
and 35 new-onset T2DM patients (21.8 ± 7.57, P <0.01).
The area under the ROC (receiver operating characteristic
curve) (Figure 5B) was 0.852, with an optimal cut off point
of 18.1/ml. MIF had a sensitivity of 86% and a specificity
of 60% to distinguish new-onset DM PC cases from
new-onset T2DM patients.
Discussion
Prognosis of pancreatic cancer is extremely poor, early
detection of pancreatic cancer appears to provide the
greatest prospect to improving long-term survival.
However, screening in the general population is now
high-cost and difficult since there is no ideal markers.
Therefore, to identify the high risk population and bio-
markers of pancreatic cancer is urgently to be addressed.
The association between pancreatic cancer and diabetes
has long been studied for hundreds of years [19]. Now
compelling studies suggest that long-term diabetes is an
etiologic factor for pancreatic cancer, while new-onset
Figure 3 The inhibitor effect of MIF on L-type voltage-dependent Ca2+ channels in mouse pancreatic β cells (HIT-T15 cell line).
(A) Representative recordings of whole-cell ICa,L are shown for the control cells, and cells treated with 20 nM, 40 nM, or 60 nM rMIF for 24 h.
(B) Representative ICa,L density– voltage relationships in control cells (n = 6) and cells treated with 20 nM (n = 6), 40 nM, or 60 nM rMIF (n = 6).
(C) A double-pulse protocol is shown with the testing potentials stepped from − 70 to 0 mV at an HP of − 40 mV. The interval between two
pulses was 10 ms. An inhibitory effect of MIF on the recovery kinetics from L-type voltage-dependent Ca2+ channels inactivation was observed.
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http://www.translational-medicine.com/content/12/1/92diabetes is its early clinical manifestations, thus the
new-onset diabetes of pancreatic cancer patients is
consider as pancreatic associated diabetes (PCDM)
[9,19,20]. It is notable that PCDM has both similarities
and differences compared with the common type 2 DM.
Common T2DM is usually associated with the metabolic
syndrome, weight gain and family history of diabetes. In
contrast, PCDM is often present in patients without
family history, and hold manifestation of weigh lost
[21]. Which indicate that the pathological mechanism
of PCDM is different from that of T2DM. Although
the pathogenesis of PCDM remains unclear, it gathered
much more attention because such understanding might
contribute to discover biomarkers for the early diagnosis
of pancreatic cancer.
Macrophage migration inhibitory factor (MIF) is a
pro-inflammatory cytokine involved in many inflamma-
tory reactions, and it has become evident that it alsoaffects glucose homeostasis through various pathways
[16]. Since MIF showed a dual regulation activity on
inflammatory and metabolic effects, it represents a logical
focus of study in the field of diabetes. In the present study,
we show that MIF is overexpressed in human PC tissue,
especially in tissues of patients with new-onset diabetes,
and is found elevated in the blood of new-onset DM PC
patients. Through the experiments, we identify that MIF
impairs insulin secretion activity of beta cell lines as
well as isolated rat pancreatic islets through regulating
Ca2+ channels function. Our find strongly suggest that
MIF is a candidate biomarker of new-onset DM PC.
Under physiological conditions, MIF is produced by
pancreatic β cells and can maintain its insulin secretion
activity [22-27], but scholars became interested in its
role in kinds of glucose metabolic disorder in recent
years, including T1DM, T2DM, gestational diabetes
mellitus (GDM), and obesity induced insulin resistance
Figure 4 Effect of MIF on LCC α1C subunit protein and Src activity in HIT-T15 cells. (A) Expression of LCC α1C subunit in HIT-T15 cells was
decreased following rMIF-treatment in a concentration dependent manner. 40 nmol/L rMIF treatment showed the most obvious suppression effect on
LCC α1C subunit expression. Top: representative Western blot analysis of LCC α1C protein in treated cells and densitometric analysis of Western blot
analysis result. Bottom: LCC α1C subunit mRNA level was also decreased along with rMIF treatment. (B) Protein tyrosine kinase inhibitors antagonized
the effect of MIF on Scr activity. Top: representative Western blot analysis of Scr activity in treated cells and controls; GAPDH was the internal control.
Bottom: densitometric analysis of Src protein in treated cells and controls. (C) Protein tyrosine kinase inhibitors antagonized the effect of MIF on
down-regulating LCC α1C protein level. Top: representative Western blot analysis of LCC α1C protein in treated cells; GAPDH was the internal control.
Bottom: densitometric analysis of LCC α1C protein in treated cells and controls. (D) Insulin secretion assay on islets and HIT-T15 cells treated with rMIF
with or without co-treatment of Src inhibitors. The inhibitory effect of rMIF on insulin secretion was eliminated by Src inhibitors. (E) In the indirect
co-culture method of islets with PC cell lines, LCC α1C subunit expression and Src activity was evaluated through Western blot analysis. Results showed
that MIF mediated the regulatory effect of PC cell lines on islets, the LCC α1C subunit expression level was in consistent with Src activity. Sh-PANC-1:
shRNA MIF-knockdown PANC-1 cell line; Sh-Capan-2: shRNA MIF-knockdown Capan-2 cell line; MIF-HPDE6: MIF-transgene overexpression HPDE6 cell
line; pGIZ-PANC-1, pGIZ-Capan-2, and pLOC-HPDE6 are null vector transfected cell lines as controls to exclude the effect of vector on expression of
potential genes coding proteins which might regulate insulin releasing.
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port a relationship MIF level and diabetes. For example,
the expression of MIF is increased in both pancreatic beta
cells and peripheral lymphocytes of mice with auto-
immune diabetes, in addition, in NOD mice treated
with rMIF the incidence of diabetes is increased from
55% to 86% [30,31]. MIF-KO mice demonstrated an
age-dependent weight gain, together with impaired
both blood glucose and insulin secretion function,
which seems like a T2DM pattern [32]. Serum
concentrations of MIF are elevated in patients with
T2DM in comparison with patients with impaired
glucose tolerance and healthy individuals [33-36]. A
significantly elevated serum MIF level in patients with
GDM compared with healthy pregnant was also
observed in a prospect study [37]. These reports are
in consist with our findings in this study that the
expression level are both increased in tissues and serum ofpatients with DM history, and support that increased
MIF expression are associated with new-onset DM PC.
Actually, MIF might be involved in diabetes pathogenesis
in much more ways: regulation the insulin secretion, modu-
lation inflammation such as exacerbates insulitis and local
pancreatic inflammation, contribute to beta cell apoptosis
in cooperate with other toxics [15,17,30,31,38-41]. Because
this present study is mainly intended to supply clinical
evidence for screening PC, we did not dig the mechanism
of the pro-diabetic effect of MIF too much, and just
explored the influence of MIF on Ca2+ channels function
and Src activity of beta cells. Since there are convincing
evidences that insulin secretion function of islet cells is
dependent largely on both L-type voltage-dependent Ca2+
channels and Src activity, our basic research findings
provided reasonable support and explanation for the
clinical data. Although MIF was reported to influence
the validity of beta cells, we just observed a slight
Figure 5 MIF is a potential biomarker of PCDM. (A) New-onset DM PC patients had the highest level of serum MIF level. (B) The receiver
operating characteristic curve (ROC) revealed a sensitivity of 86% and a specificity of 60% to distinguish new-onset DM PC cases from new-onset
T2DM patients. *:p<0.01; **:p<0.001; Student’s t-test.
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http://www.translational-medicine.com/content/12/1/92pro-apoptotic effect of rMIF on islet cells (8.3%) and
beta cells (7.5%) in high concentration (80 nmol/L
rMIF). This paradox may be explained by that its
pro-apoptotic effect depends upon cooperation with
other pro-inflammatory cytokines and toxics. Simi-
larly, Saksida T et al. also reportedβ-cells treated with
MIF along did not demonstrate a significant apoptosis
rate [15].
Importantly, serum MIF level was reported to be asso-
ciated with gender. In a large case-cohort study, elevated
serum MIF level was associated with an increased risk of
T2DM in female but not in male [34]. The reported
difference between serums MIF level in male and in
female with T2DM might linked to single nucleotide
polymorphisms and the influence of sex hormones [42].
Thus, in our present study, the long-standing DM PC
cases was choose in a same sex ratio with new-onset PC
patients, and then the controls (normal fasting glucose
group, and new-onset T2DM group) was matched to the
cases (new-onset PC group) with both age and sex in
order to avoid bias. Interestingly, in the non-cancer
new-onset T2DM group, the serum MIF levels of female
seemed to be higher than that of male (p = 0.051), but
there was no difference in serum levels of MIF
between male and female patients with new-onset
DM PC (p = 0.362). This result is probably explainedby that the onset of T2DM is more relevant to genetic
backgrounds and systematic disorder, but the pathogenesis
of PCDM is likely to be a humoral process which impairs
β cell function and peripheral insulin resistance induced
by tumor itself [8,9].Conclusions
The pathogenesis mechanism of PCDM is only starting
to be uncovered, but such understanding might yield
biomarkers which can distinguish PCDM from the more
common new-onset T2DM. In this study, we elucidated
that MIF impairs glucose-stimulated insulin secretion of
β-cells through inhibiting Ca2+ channels and regulating
Src family tyrosine kinase activity. Our study is one of
the few researches on the diabetogenic ability of pancre-
atic cancer cells, and further studies to investigate the
role of MIF as well as identify other candidate mediators
of PCDM are needed.Additional file
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